This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameSeratrodast
Accession NumberDB06739
TypeSmall Molecule
GroupsApproved
Description

Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma.

Structure
Thumb
SynonymsNot Available
External IDs A-73001 / AA-2414 / ABBOTT 73001 / ABBOTT-73001 / ABT-001
Product Ingredients Not Available
ProductsNot Available
International Brands
NameCompany
BronicaNot Available
Brand mixturesNot Available
Categories
UNII4U58JM421N
CAS number112665-43-7
WeightAverage: 354.446
Monoisotopic: 354.183109317
Chemical FormulaC22H26O4
InChI KeyZBVKEHDGYSLCCC-UHFFFAOYSA-N
InChI
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
IUPAC Name
7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
SMILES
CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Thromboxane A2 receptorProteinunknown
antagonist
HumanP21731 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Seratrodast
5-MethylhydroxyseratrodastDetails
Seratrodast
4-HydroxyseratrodastDetails
Seratrodast
Seratrodast acyl glucuronideDetails
Seratrodast
DihydroseratrodastDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Seratrodast is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Seratrodast is combined with 5-androstenedione.Experimental, Illicit
AbciximabSeratrodast may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Seratrodast can be increased when it is combined with Abiraterone.Approved
AcebutololSeratrodast may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Seratrodast.Approved
AcenocoumarolSeratrodast may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Seratrodast.Approved, Vet Approved
AclarubicinSeratrodast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Seratrodast.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alendronic acid.Approved
AliskirenSeratrodast may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololSeratrodast may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Seratrodast.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Amcinonide.Approved
AmikacinSeratrodast may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSeratrodast may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Seratrodast can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinSeratrodast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSeratrodast may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Seratrodast.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Seratrodast is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Seratrodast is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Anisodamine.Investigational
annamycinSeratrodast may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Seratrodast.Approved
Antithrombin III humanSeratrodast may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanSeratrodast may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Seratrodast is combined with Acetovanillone.Investigational
ApramycinSeratrodast may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Seratrodast.Approved, Investigational
AprepitantThe serum concentration of Seratrodast can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinSeratrodast may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinSeratrodast may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanSeratrodast may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Seratrodast.Approved, Investigational
ArmodafinilThe metabolism of Seratrodast can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololSeratrodast may decrease the antihypertensive activities of Arotinolol.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Seratrodast resulting in a loss in efficacy.Approved
AtazanavirThe metabolism of Seratrodast can be decreased when combined with Atazanavir.Approved, Investigational
AtenololSeratrodast may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Seratrodast can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Seratrodast.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Seratrodast.Approved
BalsalazideSeratrodast may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSeratrodast may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSeratrodast may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Seratrodast.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Seratrodast.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Seratrodast.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Seratrodast.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Betamethasone.Approved, Vet Approved
BetaxololSeratrodast may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Betulinic Acid.Investigational
BevantololSeratrodast may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Seratrodast can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Seratrodast.Approved, Investigational
BisoprololSeratrodast may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSeratrodast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Seratrodast can be decreased when combined with Boceprevir.Withdrawn
BopindololSeratrodast may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Seratrodast can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Seratrodast can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Seratrodast.Approved
BucillamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bucillamine.Investigational
BucindololSeratrodast may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Budesonide.Approved
BufuralolSeratrodast may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideSeratrodast may decrease the diuretic activities of Bumetanide.Approved
BupranololSeratrodast may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Seratrodast.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Seratrodast.Experimental
CapecitabineThe metabolism of Seratrodast can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Seratrodast.Approved
CarbamazepineThe metabolism of Seratrodast can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Seratrodast.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Seratrodast.Approved, Vet Approved, Withdrawn
CarteololSeratrodast may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSeratrodast may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Seratrodast.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Celecoxib.Approved, Investigational
CeliprololSeratrodast may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Seratrodast can be increased when it is combined with Ceritinib.Approved
CertoparinSeratrodast may increase the anticoagulant activities of Certoparin.Approved
ChloramphenicolThe metabolism of Seratrodast can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Seratrodast.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Seratrodast.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Seratrodast.Approved
CholecalciferolThe metabolism of Seratrodast can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Seratrodast.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Seratrodast.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Seratrodast.Approved
CimetidineThe metabolism of Seratrodast can be decreased when combined with Cimetidine.Approved
CinoxacinSeratrodast may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinSeratrodast may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Seratrodast can be decreased when combined with Citalopram.Approved
Citric AcidSeratrodast may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Seratrodast can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Seratrodast can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clonixin.Approved
ClopidogrelThe metabolism of Seratrodast can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Seratrodast.Vet Approved
ClotrimazoleThe metabolism of Seratrodast can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Seratrodast can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Seratrodast can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Seratrodast can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Seratrodast is combined with Curcumin.Investigational
CyclosporineSeratrodast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Seratrodast can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Seratrodast is combined with D-Limonene.Investigational
Dabigatran etexilateSeratrodast may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Seratrodast can be decreased when it is combined with Dabrafenib.Approved
DalteparinSeratrodast may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSeratrodast may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSeratrodast may increase the anticoagulant activities of Ym150.Investigational
DarunavirThe metabolism of Seratrodast can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Seratrodast can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinSeratrodast may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Seratrodast can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Seratrodast can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Seratrodast can be decreased when combined with Desipramine.Approved
DesirudinSeratrodast may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Seratrodast can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Seratrodast.Approved
DextranSeratrodast may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Seratrodast may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Seratrodast may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Seratrodast may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Seratrodast.Approved, Vet Approved
DicoumarolSeratrodast may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Seratrodast.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Seratrodast.Approved
DihydroergotamineThe metabolism of Seratrodast can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinSeratrodast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Seratrodast can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Seratrodast.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Seratrodast.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Seratrodast.Approved
DoxorubicinSeratrodast may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Seratrodast can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Seratrodast can be decreased when combined with Dronedarone.Approved
DrospirenoneSeratrodast may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Seratrodast is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ebselen.Investigational
Edetic AcidSeratrodast may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSeratrodast may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Seratrodast can be decreased when it is combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Seratrodast.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Seratrodast.Approved
EnoxacinSeratrodast may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinSeratrodast may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Seratrodast can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Seratrodast is combined with Epirizole.Approved
EpirubicinSeratrodast may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSeratrodast may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Seratrodast.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Seratrodast.Approved
EquileninThe risk or severity of adverse effects can be increased when Seratrodast is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Equilin.Approved
ErythromycinThe metabolism of Seratrodast can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Seratrodast can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololSeratrodast may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Seratrodast can be decreased when combined with Esomeprazole.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Estrone sulfate.Approved
Etacrynic acidSeratrodast may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Seratrodast.Approved, Investigational
Ethyl biscoumacetateSeratrodast may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Seratrodast can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Seratrodast.Investigational
FelodipineThe metabolism of Seratrodast can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Seratrodast.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Seratrodast.Vet Approved
FleroxacinSeratrodast may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Seratrodast.Approved, Withdrawn
FloxuridineThe metabolism of Seratrodast can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with fluasterone.Investigational
FluconazoleThe metabolism of Seratrodast can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fludrocortisone.Approved
FluindioneSeratrodast may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSeratrodast may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Seratrodast can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Seratrodast can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Seratrodast.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Seratrodast.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Seratrodast can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Seratrodast can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Seratrodast.Approved, Nutraceutical, Vet Approved
FondaparinuxSeratrodast may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSeratrodast may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Seratrodast.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Seratrodast can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Seratrodast can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Seratrodast.Approved
FosphenytoinThe metabolism of Seratrodast can be increased when combined with Fosphenytoin.Approved
FramycetinSeratrodast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSeratrodast may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Seratrodast can be increased when it is combined with Fusidic Acid.Approved
GabexateSeratrodast may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSeratrodast may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSeratrodast may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Seratrodast.Approved, Withdrawn
GemfibrozilThe metabolism of Seratrodast can be decreased when combined with Gemfibrozil.Approved
GemifloxacinSeratrodast may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSeratrodast may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSeratrodast may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASeratrodast may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinSeratrodast may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Seratrodast is combined with HE3286.Investigational
HeparinSeratrodast may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Higenamine.Investigational
HydralazineSeratrodast may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Seratrodast.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Seratrodast.Approved
Hygromycin BSeratrodast may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Seratrodast.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Seratrodast.Approved
IdarubicinSeratrodast may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Seratrodast can be increased when it is combined with Idelalisib.Approved
IdraparinuxSeratrodast may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Seratrodast.Approved, Investigational
ImatinibThe metabolism of Seratrodast can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Seratrodast.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Seratrodast.Approved
IndenololSeratrodast may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Seratrodast can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Seratrodast.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Indoprofen.Withdrawn
INNO-206Seratrodast may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Seratrodast can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Seratrodast can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Seratrodast can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Seratrodast is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Seratrodast can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Seratrodast is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Seratrodast can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Seratrodast can be increased when it is combined with Ivacaftor.Approved
KanamycinSeratrodast may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Seratrodast can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Seratrodast.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Seratrodast.Approved
LabetalolSeratrodast may decrease the antihypertensive activities of Labetalol.Approved
LandiololSeratrodast may decrease the antihypertensive activities of Aop200704.Investigational
LapatinibThe metabolism of Seratrodast can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Seratrodast.Approved, Investigational
LeflunomideThe metabolism of Seratrodast can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinSeratrodast may increase the anticoagulant activities of Lepirudin.Approved
LevobunololSeratrodast may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSeratrodast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Seratrodast.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Seratrodast.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Seratrodast.Approved
LomefloxacinSeratrodast may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe metabolism of Seratrodast can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Seratrodast.Approved
LosartanThe metabolism of Seratrodast can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Seratrodast can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Seratrodast is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Seratrodast.Approved, Investigational
LuliconazoleThe serum concentration of Seratrodast can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Seratrodast can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Seratrodast.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Seratrodast.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Seratrodast.Approved
ME-609The risk or severity of adverse effects can be increased when Seratrodast is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Seratrodast.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Seratrodast.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Seratrodast.Approved, Vet Approved
MesalazineSeratrodast may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Seratrodast.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Seratrodast.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Seratrodast.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSeratrodast may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Seratrodast.Approved
MetoprololSeratrodast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSeratrodast may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Seratrodast can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Seratrodast.Approved
MitotaneThe serum concentration of Seratrodast can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Seratrodast can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Seratrodast can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Seratrodast.Approved
MometasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Seratrodast.Approved
MoxifloxacinSeratrodast may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Seratrodast.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seratrodast.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nabumetone.Approved
NadololSeratrodast may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSeratrodast may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSeratrodast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe serum concentration of Seratrodast can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Seratrodast.Approved
Nalidixic AcidSeratrodast may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Seratrodast.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Seratrodast is combined with NCX 1022.Investigational
NeamineSeratrodast may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Seratrodast can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Seratrodast can be decreased when combined with Nelfinavir.Approved
NemonoxacinSeratrodast may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSeratrodast may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nepafenac.Approved
NetilmicinSeratrodast may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Seratrodast can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Seratrodast can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Seratrodast can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Seratrodast.Approved
NilotinibThe metabolism of Seratrodast can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Seratrodast.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nitroaspirin.Investigational
NorfloxacinSeratrodast may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSeratrodast may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Seratrodast can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Seratrodast.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seratrodast.Approved
OlsalazineSeratrodast may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Seratrodast.Investigational
OmeprazoleThe metabolism of Seratrodast can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Seratrodast can be increased when it is combined with Osimertinib.Approved
OtamixabanSeratrodast may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Seratrodast.Approved
OxprenololSeratrodast may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seratrodast.Withdrawn
PalbociclibThe serum concentration of Seratrodast can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pamidronate.Approved
PantoprazoleThe metabolism of Seratrodast can be decreased when combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Parecoxib.Approved
ParomomycinSeratrodast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe metabolism of Seratrodast can be decreased when combined with Paroxetine.Approved, Investigational
PazufloxacinSeratrodast may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSeratrodast may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSeratrodast may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Seratrodast can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateSeratrodast may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Seratrodast.Approved
PhenindioneSeratrodast may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Seratrodast can be increased when combined with Phenobarbital.Approved
PhenprocoumonSeratrodast may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Seratrodast.Approved, Vet Approved
PhenytoinThe metabolism of Seratrodast can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seratrodast.Approved, Investigational
PindololSeratrodast may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Seratrodast can be decreased when combined with Pioglitazone.Approved, Investigational
PirarubicinSeratrodast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSeratrodast may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Seratrodast.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Seratrodast.Approved, Investigational
PlicamycinSeratrodast may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Seratrodast.Approved
PosaconazoleThe metabolism of Seratrodast can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololSeratrodast may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Seratrodast.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Seratrodast is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Seratrodast can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Seratrodast can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Propacetamol.Approved
PropranololSeratrodast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Seratrodast.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Seratrodast.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Seratrodast.Vet Approved
Protein CSeratrodast may increase the anticoagulant activities of Protein C.Approved
Protein S humanSeratrodast may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSeratrodast may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSeratrodast may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Seratrodast.Investigational
PuromycinSeratrodast may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Seratrodast can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Seratrodast can be increased when it is combined with Quazepam.Approved, Illicit
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Seratrodast.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Seratrodast.Approved
QuinineThe metabolism of Seratrodast can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Seratrodast can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Seratrodast.Approved
RanolazineThe metabolism of Seratrodast can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Seratrodast.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Seratrodast.Experimental, Investigational
ReviparinSeratrodast may increase the anticoagulant activities of Reviparin.Approved
RibostamycinSeratrodast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Seratrodast can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Seratrodast can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Seratrodast can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Seratrodast can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanSeratrodast may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe metabolism of Seratrodast can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinSeratrodast may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Seratrodast.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Seratrodast is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Seratrodast.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Seratrodast.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Seratrodast.Experimental
SaquinavirThe metabolism of Seratrodast can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Seratrodast.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Seratrodast.Approved
SecobarbitalThe metabolism of Seratrodast can be increased when combined with Secobarbital.Approved, Vet Approved
SertralineThe metabolism of Seratrodast can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Seratrodast can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Seratrodast can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Seratrodast can be increased when it is combined with Simeprevir.Approved
SisomicinSeratrodast may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Seratrodast can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSeratrodast may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSeratrodast may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSeratrodast may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinSeratrodast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Seratrodast.Approved
SpironolactoneSeratrodast may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Seratrodast.Investigational
St. John's WortThe serum concentration of Seratrodast can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Seratrodast can be increased when it is combined with Stiripentol.Approved
StreptomycinSeratrodast may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSeratrodast may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Seratrodast can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Seratrodast can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineSeratrodast may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Seratrodast can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Seratrodast.Approved
SulodexideSeratrodast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Seratrodast.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Seratrodast.Approved, Withdrawn
TacrolimusSeratrodast may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Seratrodast.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Seratrodast.Approved
TamoxifenThe metabolism of Seratrodast can be decreased when combined with Tamoxifen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Seratrodast.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Seratrodast is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Seratrodast can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Seratrodast can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Seratrodast.Approved, Investigational
TemafloxacinSeratrodast may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Seratrodast.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Seratrodast.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tepoxalin.Vet Approved
TeriflunomideThe metabolism of Seratrodast can be decreased when combined with Teriflunomide.Approved
ThiotepaThe metabolism of Seratrodast can be decreased when combined with Thiotepa.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Seratrodast.Approved
TicagrelorThe metabolism of Seratrodast can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Seratrodast can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tiludronate.Approved, Vet Approved
TimololSeratrodast may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tixocortol.Approved
TobramycinSeratrodast may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Seratrodast can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Seratrodast can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Seratrodast.Approved
TopiramateThe metabolism of Seratrodast can be decreased when combined with Topiramate.Approved
TorasemideSeratrodast may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Seratrodast.Approved
TranilastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Seratrodast can be decreased when combined with Tranylcypromine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Seratrodast.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Seratrodast.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Seratrodast is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSeratrodast may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Seratrodast.Approved, Vet Approved
TrimethoprimThe metabolism of Seratrodast can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrovafloxacinSeratrodast may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Seratrodast.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Seratrodast is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Seratrodast can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinSeratrodast may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Seratrodast can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Seratrodast.Approved
VenlafaxineThe metabolism of Seratrodast can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Seratrodast can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Seratrodast can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinSeratrodast may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSeratrodast may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Seratrodast can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Seratrodast.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Seratrodast.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Seratrodast can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Seratrodast is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Seratrodast.Withdrawn
ZorubicinSeratrodast may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesR03DX06 — Seratrodast
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00359 mg/mLALOGPS
logP3.35ALOGPS
logP5.37ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)4.3ChemAxon
pKa (Strongest Basic)-7.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.44 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity102.37 m3·mol-1ChemAxon
Polarizability39.77 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dalbergiones. These are quinone derivatives containing a dalbergione moiety, which consists of a 1-4 quinone conjugated to a phenyl group at ring carbon 2.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassNeoflavonoids
Sub ClassDalbergiones
Direct ParentDalbergiones
Alternative ParentsMonocyclic monoterpenoids / Aromatic monoterpenoids / P-benzoquinones / Medium-chain fatty acids / Benzene and substituted derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Aldehydes
SubstituentsDalbergione skeleton / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Medium-chain fatty acid / Quinone / P-benzoquinone / Monocyclic benzene moiety / Fatty acyl / Benzenoid
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thromboxane a2 receptor activity
Specific Function:
Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl ...
Gene Name:
TBXA2R
Uniprot ID:
P21731
Uniprot Name:
Thromboxane A2 receptor
Molecular Weight:
37430.69 Da
References
  1. Endo S, Akiyama K: [Thromboxane A2 receptor antagonist in asthma therapy]. Nihon Rinsho. 1996 Nov;54(11):3045-8. [PubMed:8950952 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Uniprot Name:
Cytochrome P450 2B6
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Uniprot Name:
UDP-glucuronosyltransferase 1-9
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Uniprot Name:
Prostaglandin G/H synthase 1
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Uniprot Name:
Cytochrome P450 2A6
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on August 31, 2010 15:13 / Updated on September 01, 2017 11:30